| Gene symbol | RAF1 | Synonyms | CMD1NN, CRAF, NS5, Raf-1, c-Raf | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3p25.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | Raf-1 proto-oncogene, serine/threonine kinase | ||||
| GTO ID | GTC1225 |
| Trial ID | NCT00100672 |
| Disease | Neoplasm |
| Altered gene | C-Raf |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | LErafAON-ETU |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | Phase I Study of an Easy-to-Use Intravenous Formulation of Liposome Entrapped C-raf Antisense Oligonucleotide (LErafAON-ETU) Administered on a Weekly Schedule in Patients With Advanced Cancer |
| Year | 2005 |
| Country | United States |
| Company sponsor | INSYS Therapeutics Inc |
| Other ID(s) | LErafAON-ETU-104-R02 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||